
Lundbeck sells $100m portfolio
pharmafile | January 22, 2013 | News story | Sales and Marketing |Â Â Lundbeck, OTC, Panhematin, RecordatiÂ
Italian pharma group Recordati has paid $80 million to Lundbeck for a portfolio of products primarily aimed at the US market.
The Milan-based company expects around $40 million in revenue this year from its new acquisitions, which cost $100 million overall and include drugs for rare diseases and cancers.
Concentrating on foreign sales makes sense for Recordati: the Italian pharma market is under pressure, with branded pharma firms feeling the pinch from domestic austerity measures which have included plans to get more generics into the system.
Last November, the group acquired a series of OTC products and dietary supplements for the Russian market.
The firm’s wholly-owned US subsidiary Recordati Rare Diseases will market the drugs it has picked up from Lundbeck.
The jewel in the crown is Panhematin (haemin for injection) to help prevent recurrent attacks of acute intermittent porphyria.
NeoProfen (ibuprofen lysine injection) and Indocin IV (indomethacin injection) are both indicated for use in premature infants to close a clinically significant patent ductus arteriosus (PDA).
Meanwhile Cosmegen (dactinomycin for injection) is used in the treatment of three rare cancers.
Recordati has 3,200 staff across Europe and Turkey and concentrates on developing new candidates in cardiovascular and urogenital medicine, and on treatments for rare diseases.
Adam Hill
Related Content

Arcturus Therapeutics provides update on OTC deficiency and CF programmes
Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine …

FDA approves a second OTC naloxone nasal spray
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg …

FDA approves first OTC daily oral contraceptive pill
The US Food and Drug Administration (FDA) has announced that it has approved the Opill …






